Compare PLBC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBC | FULC |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.2M | 467.8M |
| IPO Year | 2002 | 2019 |
| Metric | PLBC | FULC |
|---|---|---|
| Price | $61.42 | $3.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $57.67 | $16.38 |
| AVG Volume (30 Days) | 53.1K | ★ 1.5M |
| Earning Date | 04-15-2026 | 04-27-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.59 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | $22.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.89 | $2.83 |
| 52 Week High | $63.74 | $15.74 |
| Indicator | PLBC | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 49.08 |
| Support Level | $51.85 | $3.44 |
| Resistance Level | $63.74 | $4.02 |
| Average True Range (ATR) | 1.35 | 0.15 |
| MACD | -0.21 | 0.05 |
| Stochastic Oscillator | 46.94 | 69.32 |
Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.